Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-kappaB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC50=12.96 µg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca2+-calcineurin-NFATc1 pathway by blocking NF-kappaB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimers disease[1][2][3][4][5].
Molekulargewicht:
386.40
Reinheit:
99.55
CAS Nummer:
[13161-75-6]
Formel:
C21H22O7
Target-Kategorie:
Cholinesterase (ChE),Keap1-Nrf2,NF-kappaB,NOD-like Receptor (NLR),Nuclear Factor of activated T Cells (NFAT),p38 MAPK,Reactive Oxygen Species (ROS)
Anwendungsbeschreibung:
MCE Product type: Natural Products
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
